Navigation Links
Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
Date:9/23/2009

SAN FRANCISCO, Sept. 23 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

"Late stage prostate cancer remains an obvious and large unmet clinical need," said David Hung, M.D., president and chief executive officer of Medivation. "However, many earlier stage prostate cancers are also inadequately treated, as evidenced by their progression, often rapidly, to late stage disease. Our ultimate goal is to develop MDV3100 for the broadest possible spectrum of prostate cancer disease states. The first step is to develop this product candidate for patients with the most advanced disease and in greatest need. However, we believe that patients with earlier-stage disease may also benefit given the attributes of MDV3100, and we look forward to expanding development to include those patients in potential future studies."

The randomized, placebo-controlled, double-blind, multi-national AFFIRM trial is expected to enroll approximately 1,200 patients at sites in the United States, Canada, Europe, South America, Australia and South Africa. The primary endpoint of the trial is overall survival; secondary endpoints include progression-free survival, safety and tolerability. This trial will evaluate MDV3100 at a dose of 160 mg taken orally once daily versus placebo.

Information about patient eligibility and enrollment can be obtained by calling the AFFIRM study hotline toll-free at 1-888-782-3256.

<
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
2. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
3. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
4. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
5. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
6. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
7. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
8. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
9. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
10. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
11. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Dec. 15 Warner Chilcott plc (Nasdaq: ... Warner Chilcott Corporation (the "Company") has commenced a ... to the conditions set forth in the Company,s ... December 15, 2009 (the "Offer to Purchase"), for ... subordinated notes due 2015 (the "Notes"). ,, The ...
(Date:12/15/2009)... -- Immucor, Inc. (Nasdaq: BLUD ), a global ... transfusion industry, today announced that it will release its ... 2010 after the market close. The Company will host ... 8:30 a.m. (Eastern Time) to discuss the results. ... conference call by dialing 1-888-324-9321 (Passcode: BLUD). Investors can ...
(Date:12/15/2009)... INCLINE VILLAGE, Nev., Dec. 15 PDL BioPharma, ... it has paid the December 15, 2009 special dividend ... shares of PDL as of December 1, 2009. ... ended December 31, 2009 total $2.67 per share. ... regarding the federal tax characteristics of the Company,s 2009 ...
Breaking Medicine Technology:Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 2Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 3Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 4Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 5Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 6PDL BioPharma Completes December 15 Special Dividend Payment 2ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 1ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 2ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 3ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 4ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 5ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 6ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 7ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 8ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 9ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 10Verenium 1 3A12 Reverse Stock Split Takes Effect 13953 1Verenium 1 3A12 Reverse Stock Split Takes Effect 13953 2Verenium 1 3A12 Reverse Stock Split Takes Effect 13953 3Verenium 1 3A12 Reverse Stock Split Takes Effect 13953 4Brain Scans Could Help Spot Schizophrenia Earlier 56674 1Brain Scans Could Help Spot Schizophrenia Earlier 56674 2
... /PRNewswire-FirstCall/ --,Alfacell Corporation's ONCONASE (ranpirnase) has shown ... antibody conjugates for cancer therapy,according to the ... , In a chapter of the text ... research indicating that the,specificity and potency of ...
... Levels in Two Most Common Mutations, CRANBURY, ... a biopharmaceutical company developing small,molecule, orally-administered pharmacological ... human genetic diseases, announced today,that it will ... (isofagomine tartrate, AT2101) for Gaucher disease at,the ...
Other Medicine Technology:Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3
(Date:12/15/2009)... released some sobering statistics concerning the parallel rise in diabetes and ... effective means of combating this trend afflicting their workforce. , ... ... diabetes are climbing across America due in large part to the ... Diabetes Association has stated that the rate of diabetes could be ...
(Date:12/15/2009)... to be leaders in the fight against malaria ... experts in online learning, the Masie Center and ... -- ONE and Malaria No More ... first-ever "Malaria Griots" program, a dynamic education course ... leaders in the fight against malaria. ,, ...
(Date:12/15/2009)... 15 4R Systems, Inc., a leading ... which help retailers significantly increase profits by optimizing ... today that The Vitamin Shoppe has been utilizing ... store and DC inventory solutions have helped us ... in-stocks over the last two years," said Tony ...
(Date:12/15/2009)... Patient advocate Betsy McCaughey, Ph.D., will ... "it doesn,t matter whether there,s a public option. The ... option - give government authority over how your doctor ... social agenda by shifting billions of dollars from Medicare ... and local politicians." ,, Betsy McCaughey is ...
(Date:12/15/2009)... CITY, Dec. 15 The new compact LifeSpan ... ( www.LifeSpanFitness.com ), was highly praised by ... treadmills for 2010. The compact TR200 folding treadmill received ... Best Treadmill under $1000. ,, The compact LifeSpan ... in small workout spaces. "This category buster is a ...
Breaking Medicine News(10 mins):Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 3Health News:ONE and Malaria No More Launch 'Malaria Griots' 2Health News:ONE and Malaria No More Launch 'Malaria Griots' 3Health News:ONE and Malaria No More Launch 'Malaria Griots' 4Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 3Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 4Health News:Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill 2
... been proposed by Pharmac, to hold a meeting regarding extension ... the provision of drug to women with early breast cancer. ... advanced breast cancer. Extension of the budget for the cancer ... planned. , ,The company officials are much more ...
... the available treatment methods, it is the socioeconomic status ... cancer, according// to a new study published in the ... of the American Cancer Society. ,The study found ... equally important role in determining the outcomes as did ...
... promoted by India's pharma major Ranbaxy Laboratories, Monday announced the ... can give results in just a day. ,"A first ... bird flu that can be effectively employed for mass screening ... to ten days, which other available tests take," said SRL ...
... a public display of their affection here on Valentine's Day ... by some young lovers. ,Youngsters have got over the ... on lovers by the Akhil Bharatiya Vidhyarthi Parishad (ABVP), the ... ,The move is now being welcomed by courting couples, who ...
... to donate nearly 100 acres of land to guru Baba ... has also been invited to set up a facility for ... state reserve of medicinal plants. ,The government is ... next week when he arrives here for a yoga camp ...
... urged that people restrict their telephonic conversations to a minimal ... phones. ,Germany's federal bureau for radiation protection (BfS) ... to put the base station in an area of their ... The foyer or entrance is a good example. ,The ...
Other Medicine News:
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
... Nile Virus IgG DxSelect is intended,for ... Nile virus in human,serum. In conjunction ... Virus,IgM Capture DxSelect, the test is ... meningioencephalitis, as an aid in the,presumptive ...
... PachPen uses state-of-the-art waveform analysis ... at a 65MHz rate to ... stores and averages nine measurements ... pen fits comfortably into the ...
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
Medicine Products: